Charo LM, Jou J, Binder P, et al. - Researchers sought report on the relative frequency of HIPEC use in ovarian cancer treatment before and after publication of the phase 3 study by van Driel et al. in January 2018. In addition, they compared the associated rates of hospital-based outcomes, including length of stay, intensive care unit (ICU) admission, complications, and costs in ovarian cancer surgery with or without HIPEC. Searching Vizient's administrative claims database of 550 US hospitals, they identified 152 ovarian cancer patients who had HIPEC at 39 hospitals, and 20,014 ovarian cancer patients who underwent surgery without HIPEC at 256 hospitals. Ninety-seven percent (97%) of HIPEC cases occurred following the trial publication. Observations revealed a rise in HIPEC use for ovarian cancer in US after phase 3 trial publication, though absolute number of cases remains modest. Incorporation of HIPEC was noted to be linked with increased cost, hospital length of stay, ICU admission, and hospital-acquired complication rates.